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Abstract
ACE inhibitor drugs decrease mortality by up to one-fifth in cardiovascular patients. Surprisingly, there are reports dating
back to 1979 suggesting the existence of endogenous ACE inhibitors. Here we investigated the clinical significance of this
potential endogenous ACE inhibition. ACE concentration and activity was measured in patient’s serum samples (n = 151).
ACE concentration was found to be in a wide range (47–288 ng/mL). ACE activity decreased with the increasing
concentration of the serum albumin (HSA): ACE activity was 5661 U/L in the presence of 2.460.3 mg/mL HSA, compared to
3961 U/L in the presence of 1261 mg/mL HSA (values are mean6SEM). Effects of the differences in ACE concentration
were suppressed in human sera: patients with ACE DD genotype exhibited a 64% higher serum ACE concentration (range,
74–288 ng/mL, median, 155.2 ng/mL, n = 52) compared to patients with II genotype (range, 47–194 ng/mL, median,
94.5 ng/mL, n = 28) while the difference in ACE activities was only 32% (range, 27.3–59.8 U/L, median, 43.11 U/L, and range
15.6–55.4 U/L, median, 32.74 U/L, respectively) in the presence of 1261 mg/mL HSA. No correlations were found between
serum ACE concentration (or genotype) and cardiovascular diseases, in accordance with the proposed suppressed
physiological ACE activities by HSA (concentration in the sera of these patients: 48.560.5 mg/mL) or other endogenous
inhibitors. Main implications are that (1) physiological ACE activity can be stabilized at a low level by endogenous ACE
inhibitors, such as HSA; (2) angiotensin II elimination may have a significant role in angiotensin II related pathologies.
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Introduction
The renin-angiotensin-aldosterone system (RAAS) is an impor-
tant regulator of blood pressure and salt-water homeostasis.
Angiotensin converting enzyme is a member of RAAS [1], which
catalyses the cleavage of angiotensin I to angiotensin II, and takes
part in the metabolism of other peptides like bradykinin [2].
ACE is a prime target in the treatment of common diseases,
hereby ACE inhibitors represent one of the most commonly used
drugs. This is supported by the fact, that there were 162.8 million
ACE inhibitor prescriptions in 2009 in the United States of
America [3], which will probably increase during the next years.
Their effectiveness is proven by several large clinical trials: ACE
inhibitors reduce the risk of cardiovascular death, nonfatal
myocardial infarction or cardiac arrest in stable coronary heart
disease [4], improve the prognosis [5] and reduce the 5-week
mortality after myocardial infarction [6], reduce heart failure
mortality [7], inhibit left ventricular remodeling [8], delay the
manifestation of hypertension [9], and reduce the left ventricular
mass index in left ventricular hypertrophy [10], the incidence of
microalbuminuria and the risk of diabetic nephropathy in type 2
diabetes [11] and the likelihood of newly diagnosed diabetes
mellitus [12]. The latest therapeutic guidelines have already
incorporated all these evidences [13–18], and ACE inhibitors are
kept on record as a promising component of polypills in primary
prevention of large mortality diseases [19].
Motivated by the obvious effectiveness of ACE inhibitors, efforts
have been made to associate ACE expression with cardiovascular
pathologies to introduce personalized therapies. The clinical
efficacy of ACE inhibitors appears to be genetically determined,
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as ACE inhibitors are less effective in African-American patients
than in Caucasian patients [20]. Genetic studies have revealed that
the expression of ACE is controlled by an insertion/deletion (I/D)
polymorphism in the ACE gene, which results in an ACE
expression that is approximately 50% higher in individuals with
genotype DD than in those with genotype II [21]. Although some
later reports downgraded the level of contribution of ACE
genotype to ACE expression (about 20% [22,23] or only 8%
[24]), ACE genotype has been studied extensively as a major
cardiovascular risk factor.
Recently, we have confirmed that the human serum albumin
(HSA) is an endogenous ACE inhibitor [25]. HSA antagonized
serum ACE activity with an IC50 value of 5.760.7 mg/mL [25],
while physiological HSA concentrations were in the 35–52 mg/
mL range in our studies. These data suggested that ACE is
significantly inhibited by HSA, in vivo.
The goal of our study was to validate endogenous ACE
inhibition in clinical studies. Recently we have found that
endogenous ACE inhibitors [26] such as human serum albumin
(HSA) [25] stabilize angiotensin converting enzyme (ACE) activity
at a very low level [25,26] independently of ACE expression levels.
In accordance, ACE expression and ACE genotype had no effect




All of the studies were approved by the Regional and
Institutional Ethics Committee, Medical and Health Science
Center, University of Debrecen, (UDMHSC REC/IEC number:
2894-2008) and by the Medical Research Council of Hungary. All
of the patients involved gave their written informed consent.
Patient’s blood sample collection, serum and DNA
isolation
Blood samples were collected from volunteers by using a
standard aseptic technique. Native blood was incubated for
60 minutes at room temperature; serum fractions (separated by
centrifugation at 1,500 g for 15 min) were stored at 220uC until
further experiments. Genomic DNA was prepared from antico-
agulated venous blood by using a DNA separation kit (Qiagen).
ACE activity measurement
ACE activity was measured as originally described by Beneteau
et al. [27] and modified by us [26]. In brief, ACE activity was
determined with an artificial substrate (FAPGG, (N-[3-(2-furyl)a-
cryloyl]-L-phenylalanylglycylglycine; Sigma-Aldrich) in a reaction
mixture containing 25 mM HEPES (N-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid), 0.5 mM FAPGG, 300 mM NaCl, and
the desired dilution of serum, at pH 8.2. Measurements were
performed in 96-well plates (Greiner-Bio One) at 37uC. Changes
in optical density (340 nm) were measured at 5-min intervals for at
least 90 min with a plate reader (NovoStar plate reader; BMG
Labtech). Optical density values were plotted as a function of
reaction time and fitted by linear regression. The fit and the data







where S is the rate of observed decrease in optical density (1/min),
k is the change in optical density upon the complete cleavage of
1 mmol of FAPGG, and D is the dilution of the serum. ACE
activity is given in units where 1 U is equivalent to the cleavage of
1 mmol of FAPGG in 1 min. In some experiments, the reaction
mixture also contained human serum albumin (HSA; Human
BioPlazma Manufacturing and Trading).
Measurement of human serum albumin concentration
Human serum albumin concentration was measured with
bromocresol green (BCG, Dialab) diagnostic reagent according
to the manufacturer’s instructions. Briefly, 10 ml serum sample was
added to 1 mL bromocresol green reagent (260 mM bromocresol
green in 30 mM citrate buffer, pH 4.2), and the mixture was
incubated for 10 minutes at room temperature. The absorbance of
the mixture was measured at 546 nm against reagent blank in a
spectrophotometer (U-2900, Hitachi), using disposable cuvettes.






where A is the absorbance of mixture at 546 nm, Cstandard is the
HSA concentration of a diagnostic standard (Albumin standard,
Dialab).
Determination of ACE I/D polymorphism
The insertion/deletion genotype (I/D) of ACE was determined
by PCR amplification of alleles I and D on the basis of the
standard protocol described by Rigat et al. [28]. The amplification
products were separated on 5% polyacrylamide gels, and were
visualized by ethidium-bromide staining. The presence of allele I
or D resulted in a 490-bp or a 190-bp PCR product, respectively
(Fig. 1). Insertion specific polymerase chain reaction was
performed to avoid mistyping ID and DD genotypes using a
protocol described by Lindpaintner et al. [29]. In this case the
presence of allele I resulted in a 335-bp amplicon visualized on 3%
agarose gel (Fig. 1).
Measurement of serum ACE concentration
Serum ACE concentration was measured by a commercial
human ACE ELISA development kit (R&D Systems) according to
the manufacturer’s instructions, with minor modifications. Briefly,
enzyme-linked immunosorbent plates (Greiner Bio-One) were
coated with 80 ng/well capture antibody, and the remaining
binding sites were then blocked with reagent diluent (10 mg/mL
bovine serum albumin (Sigma-Aldrich) in Dulbecco’s phosphate-
buffered saline solution (PBS, Gibco)). Diluted sera (in reagent
diluent, 12.5–200-fold dilution) were added to the wells, and the
antibody-antigen complexes were labeled with a biotinylated
detection antibody (20 ng/well). 200-fold-diluted streptavidin-
conjugated horseradish-peroxidase (kit component) was added to
the wells. Finally, the amounts of complexes were detected with a
substrate solution containing 0.3 mg/mL tetramethylbenzidine,
0.1 mM H2O2 and 50 mM acetic acid. The reaction was
terminated after 20 min by the addition of 0.5 M HCl, and the
optical density was measured at 450 nm. To determine the
optimal conditions to measure ACE concentration in human sera
with II, ID and DD genotypes a series dilutions were tested (12.5–
200-fold, Fig. 2). The 100-fold dilution was found to be optimal:
the values were in the linear phase (in contrast with dilutions below
50-fold dilutions) and were sufficiently high to measure. The ACE
concentrations in the samples were measured at least three times
to achieve a standard deviation of at most 15%.
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Calculation of ACE activity in the undiluted human sera
ACE activity in the undiluted sera was calculated according to
the equation:
Ki~
Active ACE½ | HSA½ 
Inactive ACE½ 
Where Ki is the inhibitory constant of HSA on ACE activity
determined previously (83 mM) [25], [Active ACE], concentration
of the active form of ACE; [Inactive ACE], concentration of the
inhibited form of ACE; [HSA], concentration of human serum
albumin, determined by colorimetric assay.
Taking into account that
Total ACE½ ~ Active ACE½ z Inactive ACE½ 
where [Total ACE] is determined by ELISA,
[Active ACE] can be calculated based on measured values as:
Active ACE½ ~Ki| Total ACE½ 
HSA½ zKi :
Activity of [Active ACE] was related to the measured ACE activity
in the same patients at 20-fold dilution, where ACE activity was
considered to be uninhibited by HSA [25], to estimate the ACE
activity in the undiluted human sera.
Statistical analysis
Statistical analysis was performed with Graphpad Prism 5.0
(GraphPad Software) by one-way ANOVA, one-way ANOVA
with Dunnett’s multiple comparison test and by the t-test.
Differences were considered to be significant when p,0.05.
Results
Plotting ACE activity as a function of the serum ACE
concentration yielded a linear relationship in the individual
patients (Fig. 3A), and in patient groups with different levels of
endogenous ACE expression (Fig. 3B). However, a 5-fold increase
in serum ACE concentration was only accompanied by a 2.3-fold
increase in serum ACE activity based on the linear fit of the
individual values (Fig. 3A). Similarly, the increase in serum ACE
concentration from 62611 ng/mL to 252632 ng/mL (4.1-fold
increase in expression, Fig. 3B) was accompanied by a limited (2.1-
fold) increase in ACE activity (from 2767 U/L to 5662 U/L,
Fig. 3B).
Patients who were homozygous for the allele D (deletion) of the
ACE gene displayed higher ACE concentrations in their sera than
those who were homozygous for the allele I (Insertion, II = 47–
194 ng/mL, median: 94.5 ng/mL, n=28; ID= 36–202 ng/mL,
median: 114.3 ng/mL, n=71; DD=74–288 ng/mL, median:
155.2 ng/mL, n=52; Fig. 4A). The activity of ACE was also
elevated in the DD homozygote patients (II = 15.6–55.4 U/L,
median: 32.74 U/L, n=28; ID=15.2–59.3 U/L, median:
35.48 U/L, n=71; DD=27.3–59.8 U/L, median: 43.11, n=52;
Fig. 4B). Nonetheless, these data indicate that a 64% increase in
Figure 1. Determination of ACE genotype. ACE genotype was determined by PCR based assays. First, PCR was performed according to the
method described by Rigat et al. (indicated). Amplified DNA with a size of 490 bp represented the I allele, while D allele resulted in a 190-bp band.
The results were then verified by the method described by Lindpaintner et al. (indicated). Allele I resulted in a 335-bp amplicon in this case.
doi:10.1371/journal.pone.0093719.g001
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serum ACE concentration results in only a 32% increase in ACE
activity in patients with the DD genotype versus those with the II
genotype.
These data suggest that the ACE activity is modulated by
additional factors besides the ACE concentration in the human
serum [26]. Previous results suggested that serum albumin is an
endogenous ACE inhibitor [25,30], which has a concentration
dependent effect on serum ACE activity. An effort was made to
investigate the relationship between serum ACE activity and
serum albumin concentration in human sera under in vitro
conditions. Apparent specific ACE activity was higher when
serum albumin concentration was low due to the dilution of the
sera (Fig. 5). In particular, apparent specific ACE activity
decreased from 56.1361.17 to 38.5560.78 U/L when HSA
concentration increased from 2.4260.02 mg/mL to
12.1260.12 mg/mL. The stability constant (IC50 value) of the
human serum ACE-HSA interaction was 5.760.7 mg/mL in a
previous study in our laboratory [25], suggesting that the ACE
activity is 8.4760.18 U/L (calculated values) in the presence of
Figure 2. Determination of ACE concentration. Three patients were selected to represent all genotypes (II, ID and DD, indicated). Sera were
diluted 12.5, 25, 50, 100 and 200-fold (indicated) to determine optimal conditions. ACE amount was determined in an ELISA assay. A set samples with
known ACE concentrations (Standard, A) were also used. Values (optical density) were plotted as the function of the known ACE concentration and a
calibration curve was defined (nonlinear fit, solid line, A). Concentrations of the serum samples were then calculated based on their position on the
calibration curve. Each serum sample was determined two times. Average of the quadruple measurements is shown (three samples measured twice,
resulting in 6, sometimes overlapping individual data point for each dilution, A). It was apparent from the individual measurements that dilutions at
200-fold have very low values, while the saturation of the binding sites resulted in a high scatter at dilutions below 50-fold (A). Although averaged
values showed a tendency for under-estimating ACE concentrations at low dilutions, in the case of high expression levels (B), ACE concentration
determination was remarkably accurate. Bars represent mean 6 SD. No statistical differences were found by nonparametric ANOVA.
doi:10.1371/journal.pone.0093719.g002
Disease Protection by Endogenous ACE Inhibition
PLOS ONE | www.plosone.org 4 April 2014 | Volume 9 | Issue 4 | e93719
the measured 48.4660.46 mg/mL HSA concentrations in human
serum samples used for the analysis (Fig. 5).
It was tested whether this endogenous suppression of serum
ACE by HSA is sufficient to compensate for different expression
levels in hypertensive patients where therapeutic ACE inhibition is
particularly effective. Patients without prescribed ACE inhibitory
drugs were recruited (n = 151 patients, Table 1). Serum ACE
concentration did not correlated with morphometric parameters
such as age, body mass, height or body mass index (Fig. 6). Serum
ACE concentration did not show correlation with lipid parame-
Figure 3. Incomplete correlation between serum ACE concentration and activity. Serum ACE concentration and specific ACE activity was
determined in hypertensive patients (n = 151 patients). Serum ACE concentration was determined by an ELISA method using 100-fold diluted serum
samples. Human recombinant ACE was used to construct calibration curves for each individual plate. Serum ACE expression was calculated based on
these calibration curves. ACE activity was assessed at a 4-fold dilution by measuring the decomposition of the artificial substrate FAPGG. Serum ACE
activity is shown as a function of the serum ACE concentration in the figures. Panel A shows the individual data, while patients were grouped
according to their serum ACE concentration in panel B. Both graphs were fitted by a linear regression to reveal correlations between the values, and
the parameters of the fits are shown. The magnitude of the differences in ACE concentration and ACE activity values are also shown. Symbols
represent the mean (measurements were done at least 3-times), bars are SEM.
doi:10.1371/journal.pone.0093719.g003
Figure 4. ACE genotype determines serum ACE concentration and activity. Serum ACE concentration, activity and genotype was
determined as mentioned earlier (Figs. 3, 1). ACE concentration (A) and activity (B) in patients with different ACE genotypes (insertion, II, n=28;
deletion, DD, n=52 and heterozygotes, ID, n= 71) are shown. The boxes indicate the interquartile range with median; whiskers are the minimum and
the maximum values. Significant differences (1 way ANOVA, Bonferroni post-hoc test) are labelled by asterisks (NS, not significant).
doi:10.1371/journal.pone.0093719.g004
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ters, such as total cholesterol and triglyceride concentration (Fig. 7).
Cardiovascular parameters (ejection fraction, heart rate, systolic
and diastolic blood pressure) were again independent of serum
ACE concentration (Fig. 8), based on the inaccurate fit (repre-
sented by the low r2 values). Parameters of the renal function
(serum urea, creatinine, uric acid and glomerular filtration rate)
again showed a significant scatter (see low r2 values) and suggested
no correlation with serum ACE concentration (Fig. 9). Correlation
of these values was also tested with the genotype of the patients,
which significantly affected ACE expression (Fig. 4A). No
correlation was found between clinical parameters and ACE
genotype (Fig. 10), similarly to the individual ACE expression
levels (Fig. 6–9).
Discussion
Angiotensin converting enzyme (ACE) is one of the most
frequently targeted enzymes in the everyday medical practice.
ACE inhibitors are the fifth most described drugs and represent a
cornerstone in the treatment in cardiovascular diseases (hyperten-
sion, heart failure) [13–18]. Surprisingly, we have confirmed
recently [25], that serum albumin is an endogenous ACE inhibitor
[31], which can inhibit ACE in a concentration dependent fashion
(IC50 value is 5.760.7 mg/mL on human serum ACE in our
studies [25]) similarly to the prescribed ACE inhibitory drugs.
We hypothesized here that endogenous ACE inhibitors [26,32–
45], such as human serum albumin [25] can provide an
endogenous protection against dysregulation of ACE. Our recent
data suggest that serum ACE activity is suppressed by endogenous
ACE inhibitors [26], such as serum albumin [25], providing a
protection against higher ACE expression levels in human serum
[25].
Determination of ACE concentration was done by a kit
manufactured by R&D Systems here. Since we did not find
relevant publications using this kit to determine serum ACE, we
have performed a detailed analysis of its reproducibility and made
an effort to optimize the conditions. It appeared that the
determinations are remarkably reproducible in a wide range of
serum dilutions (12.5–200-fold). Nonetheless, 100-fold dilution
appeared to be optimal (measurable values using limited volumes
of serum samples). Values determined by this kit appeared to be
somewhat lower than that published before (400–584 ng/mL)
[23,46,47]. The reason of the differences can be related to the
purity and quality of the standards used to quantitate concentra-
tions. Irrespectively to the differences in the values determined by
different methods, it appeared that our method results in an
accurate determination of the differences in ACE concentration.
These concentrations correlated by the genotype of the individuals
(about 64% higher ACE concentration in patients with DD
genotype compared to patients with II genotype).
ACE insertion-deletion (I/D) polymorphism was identified more
than 20 years ago [21], and it was postulated that this polymorphism
is responsible for 20–50% of the interpersonal variability in
circulating ACE expression levels. In accordance, we found a wide
range in serum ACE expression in human sera (from 47 to 288 ng/
mL) and patients with DD genotype had 64% higher ACE
expression than patients with II genotype. It was proposed that the
differences in ACE expression related to ACE I/D polymorphism
may play a role in the occurrence of myocardial infarction, coronary
artery disease, coronary artery calcification, heart failure and
hypertension. No such correlation was found here, in accordance
with a meta-analysis of more than 30,000 individuals which
concluded that ACE genotype is without effects on blood pressure,
and is not associated with an increased risk of myocardial infarction,
ischemic heart disease or ischemic cerebrovascular disease [48].
Figure 5. Serum ACE activity correlates with serum albumin concentration. Serum ACE activities (n=151 patients) were determined at
different dilutions (20-fold and 4-fold dilutions). The determined ACE activity values were plotted as a function of the actual serum albumin
concentrations in the individual samples (A). Serum ACE activity values for undiluted sera were estimated based on the measured activity values at
20-fold dilution and the reported ACE-HSA inhibitory constant (IC50 = 5.7 mg/mL). These calculated ACE activity values were plotted as a function of
the measured human serum albumin concentration in the individual serum samples (labelled as undiluted sera). Values are also given as the mean
and SD of the individual determinations (B). There was a significant difference (unpaired t-test) between the values measured at 20-fold and 4-fold
dilutions (indicated).
doi:10.1371/journal.pone.0093719.g005
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In the present study, we directly tested the relationship between
ACE expression and activity in sera obtained from hypertensive
patients. It was found that hypertensive patients with DD genotype
had 64% higher serum ACE concentrations than in those with II
genotype, while the difference in ACE activities was only 32%.
This suggested that the effects of higher ACE expression are
Figure 6. There is no relationship between morphometric parameters and serum ACE concentration. Age, body mass, height and body
mass index of the patients involved in the studies (n=151) are plotted as the function of the measured serum ACE concentration. Points were fitted
by a linear regression to reveal the potential correlation between the plotted parameters. Parameters of the fitting are shown in each graph. The
normal range for BMI is 18.5–25 kg/m2.
doi:10.1371/journal.pone.0093719.g006
Figure 7. There is no relationship between serum lipid levels and serum ACE concentration. Total cholesterol and triglyceride levels are
plotted as a function of the serum ACE concentration (n= 151 patients). Points were fitted by a linear regression to reveal the potential correlation
between the plotted parameters. Parameters of the fitting are shown in each graph. Normal rage for total cholesterol is lower than 5.2 mmol/L for
triglyceride is lower than 1.7 mmol/L.
doi:10.1371/journal.pone.0093719.g007
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buffered. These findings are in accordance with the observation
that local angiotensin I to angiotensin II conversion and the
angiotensin II/I ratio are independent of the I/D genotype in the
human forearm [49].
This apparent lack of correlation between cardiovascular
parameters and ACE expression (genotype) is particularly
interesting in light of the clinical effectiveness of ACE inhibitors
for the same cardiovascular diseases, as evidenced by several large-
scale trials, and as accepted by the published guidelines [4–18].
Several recent reviews evaluating the potential role of an increased
ACE expression in cardiovascular disease concluded that not the
expression (and genotype), but the actual ACE activity is
important [50].
Important to note, that it is rather complicated to accurately
determine serum ACE activity. In particular, earlier reports
suggested that dilution of the serum has a significant effect on the
apparent ACE activity values [32]. To eliminate this effect a high
dilution factor was suggested during the determinations [51]. In a
recent work we have identified the serum albumin as an
endogenous ACE inhibitor, with an IC50 value (5.760.7 mg/
mL) [25]. It was found that the apparent serum ACE activity is
higher and the effect of dilution is missing when serum albumin is
removed from the human sera [25,26].
The major novelty of the present work is to show that
endogenous inhibitors [26], such as HSA [25] suppress ACE
activity in a clinical setup. Serum ACE activity did not correlate
perfectly with the ACE concentration. A 4.1-fold increase in ACE
concentration resulted in a 2.1-fold increase in ACE activity in the
patient’s sera, suggesting that serum ACE activity is regulated.
Additional factors than the concentration of the enzyme contribute
to the ACE activity. Moreover, this factor suppressed the effects of
the different ACE expression levels on ACE activity, suggesting the
existence of an endogenous ACE activity stabilizing mechanism.
This effect may be clinically significant when the circulating
ACE level is elevated in consequence of genetic factors (such as the
ACE I/D polymorphism) or diseases. A point mutation in the stalk
region of the ACE gene resulted in a 5-fold elevated circulating
ACE concentration [52]. This mutation affected at least eight
families, but there were no ACE-related clinical abnormalities or
hypertension. An other mutation that was accompanied by a 13-
fold elevation of the serum ACE concentration was also without
increased occurrence of cardiovascular disease [53]. Some other
mutations of the ACE gene are known to be coupled with a mildly
elevated ACE concentration, but again without an enhanced
incidence of cardiovascular diseases [54–57]. All of these
observations suggest that substantial differences in ACE concen-
trations are well tolerated in vivo. This tolerance can be explained
Figure 8. There is no relationship between cardiovascular parameters and serum ACE concentration. Cardiovascular parameters
(ejection fraction, heart rate, systolic and diastolic blood pressure) were plotted as a function of the serum ACE concentration (n= 151 patients).
Points were fitted by a linear regression to reveal the potential correlation between the plotted parameters. Parameters of the fitting are shown in
each graph. Ejection fraction is normally above 50%, heart rate is in the range of 60–100/min, systolic and diastolic blood pressure is in the range of
90–140 and 60–90 mmHg.
doi:10.1371/journal.pone.0093719.g008
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by the observation that ACE activity is stabilized at a low level by
endogenous factors [25,26].
Unfortunately it was not possible to directly determine ACE
activity in the undiluted human sera. ACE activities were
measured at a 4-fold dilution because serum absorbed light
significantly at 340 nm, where exogenous substrate conversion is
detected. Nonetheless, ACE activity was estimated in undiluted
human serum by measuring the serum albumin and ACE
concentrations, ACE activity at 20-fold dilution and using the
previously determined inhibitory constant for HSA on human
serum ACE (IC50 = 5.760.7 mg/mL) [25]. According to these
measured values and the calculations ACE activity is suppressed to
8.562.2 U/L by the physiological concentration of HSA in the
undiluted human serum samples. Moreover, this ACE activity is
only the maximal value (representing the isolated effect of HSA).
Other proposed endogenous ACE inhibitory molecules may
further suppress ACE activity, in vivo [26].
The measured concentrations of ACE (about 127 ng/mL) and
serum albumin (about 48 mg/mL) in human serum samples
suggest that differences in ACE concentration may be buffered by
endogenous inhibitors [26], in particular by HSA [25]. Serum
albumin is present at concentration of 10-fold higher than the IC50
value for HSA to inhibit ACE suggesting that the majority of ACE
is in its HSA bound (inhibited) form. Free HSA concentration is
negligibly affected by ACE binding, several orders of magnitude
differences in ACE activity can be theoretically ‘‘buffered’’ by
binding to HSA.
It needs to be mentioned that HSA is only one of the proposed
endogenous ACE inhibitors. Existence of endogenous ACE (called
kininase II at this time) inhibitors were proposed as early as 1979.
Besides to Klauser et al., who reported first that serum albumin
inhibits the ACE [30] Ryan et al. reported the existence of small
(,10 kDa) molecular weight components of human sera [39].
Later studies identified substrate analogues (angiotensin I [45] and
substance P [44]) able to inhibit ACE. Lieberman et al. reported
an ACE inhibitor with an apparent molecular mass of .50 kDa
[32], Ikemoto et al. reported an inhibitor with an apparent
molecular mass of .10 kDa [38]. Both low and high molecular
weight ACE inhibitors were shown in the rat lung [33] or in the
human sera [58]. Peptides of the tryptic lysate of human plasma
[35,36], human serum albumin [59], bovine alphaS2-casein [43]
and some types of honey were also found to inhibit ACE [41].
Taken together, it appears that HSA (and/or its fragments) has
an effect on ACE activity, in vivo. On the other hand HSA is
probably not the sole endogenous inhibitor of ACE, according to
these reports, making it hard to estimate its contribution. We
proposed a hypothesis, which was based on the effect and
concentration response of HSA [25], which in itself appeared to be
Figure 9. There is no relationship between parameters of renal function and serum ACE concentration. Renal function was assessed by
the means of urea, creatinine and uric acid concentrations in the sera and by the glomerular filtration rate (GFR) values. Values were plotted as a
function of the serum ACE concentration (n=151 patients). Points were fitted by a linear regression to reveal the potential correlation between the
plotted parameters. Parameters of the fitting are shown in each graph. Normal ranges for the values are: urea, 3.6–7.2 mmol/L, creatinine, 44–
97 mmol/L (female) and 62–106 mmol/L (male), GFR, above 90 mL/min/1.73 m2, uric acid, 140–340 mmol/L (female) and 220–420 mmol/L (male).
doi:10.1371/journal.pone.0093719.g009
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sufficient to explain the findings. This hypothesis was indirectly
tested in this manuscript and other endogenous ACE inhibitors
may also have contributed to the features described here.
The observed suppression of serum ACE activity provides basis
for intriguing consequences. One of them is that physiological
angiotensin II concentrations may be determined by angiotensin II
elimination. In this case activation of RAAS, which is a
cornerstone of cardiovascular diseases (such as hypertension and
heart failure) may occur by the decreasing efficiency of angiotensin
II elimination as has been shown in an accompanying clinical
paper [60]. As a matter of fact, one of the best-characterized
enzymes involved in angiotensin II elimination is ACE2 [61],
activation of which is known to protect against hypertension,
myocardial fibrosis, remodeling [62] and renal impairment [63].
Another implication is that the levels of these endogenous
inhibitors (including HSA) may affect the function of the RAAS
through modulating ACE activity. Our data suggest that ACE is
well suppressed as long as the HSA concentration is at least
,30 mg/mL. Indeed, postoperative infusion of HSA frequently
evokes hypotension in patients receiving ACE inhibitor therapy
[64].
In summary, our data suggest that human serum ACE activity is
suppressed at a low level (buffered) by endogenous inhibitors [26],
such as serum albumin [25] and probably other low molecular
weight inhibitors. This suppression of serum ACE activity suggests
that angiotensin II synthesis may be limited, in which case
angiotensin II elimination may have a significant physiological role
[60]. Moreover, clinical data provided here suggest that this
suppression of physiological ACE activity may contribute to the
tolerance of different ACE expression levels, such as determined
by ACE I/D polymorphism.
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Figure 10. Correlation of patient’s parameters with ACE I/D genotype. Various parameters (age, body mass, height, body mass index, total
cholesterol, triglyceride, ejection fraction, heart rate, systolic and diastolic blood pressure, urea, creatinine, glomerular filtration rate and uric acid)
were correlated to the genotype of the patients (insertion, II, n= 28; deletion, DD, n=52 and heterozygotes, ID, n= 71). The boxes indicate the
interquartile range with median; whiskers are the minimum and the maximum values. Significant differences (1 way ANOVA, Bonferroni post-hoc test)
are labelled by asterisks.
doi:10.1371/journal.pone.0093719.g010
Disease Protection by Endogenous ACE Inhibition
PLOS ONE | www.plosone.org 10 April 2014 | Volume 9 | Issue 4 | e93719
Table 1. Clinical parameters and the genotype of the patients involved in the study.
II ID DD All patients
Number of patients 28 71 52 151
Gender (female/male) 12/16 33/38 36/16 81/70
Age 58611 58614 52613 56613
Body mass Index (kg/m2) 28.965.6 29.265.9 29.065.0 29.066.0
Smoker 4 (14%) 15 (21%) 7 (13%) 32 (21%)
Diabetes mellitus IDDM 2 (7%) 3 (4%) 3 (6%) 8 (5%)
NIDDM 6 (21%) 13 (19%) 8 (15%) 27 (18%)
Dyslipidemia 19 (68%) 48 (68%) 32 (62%) 99 (66%)
Total cholesterol (mmol/L) 4.9661.34 5.2161.38 5.2861.39 5.1961.36
Ejection fraction (%) 5766 5668 5967 5767
Heart rate (1/min) 71610 75612 75613 74612
Systolic blood pressure (mmHg) 130621 128616 128616 129617
Dyastolic blood pressure (mmHg) 81612 8069 78610 80610
Urea (mmol/L) 7.362.3 5.662.7 5.461.9 5.862.3
Creatinine (mmol/L) 85629 82652 71617 77638
Glomerular filtration rate (mL/min/1.73 m2) 75621 87625 85612 84620
Uric acid (mmol/L) 3566126 3136101 313672 319694
ACE amount (median (min, max), U/L) 95 (47, 194) 114 (36, 202) 155 (74, 288) 127 (36, 288)
ACE activity (median (min, max), ng/mL) 33 (16, 55) 35 (15, 59) 43 (27, 60) 38 (15, 60)
Used antihypertensive drugs:
Diuretics 15 (54%) 23 (32%) 16 (31%) 54 (36%)
Clopamide 0 1 (1%) 0 1 (0.5%)
Hydrochlorothiazide 10 (36%) 13 (19%) 13 (25%) 36 (24%)
Indapamide 0 3 (4%) 0 3 (2%)
Spironolactone 3 (11%) 3 (4%) 3 (6%) 9 (6%)
Amiloride 2 (7%) 3 (4%) 0 5 (3%)
b-Blockers 21 (75%) 51 (72%) 32 (62%) 104 (68%)
Betaxolol 0 1 (1%) 0 1 (0.5%)
Bisoprolol 11 (40%) 24 (34%) 19 (37%) 54 (36%)
Carvedilol 2 (7%) 5 (7%) 2 (4%) 9 (6%)
Metoprolol 2 (7%) 5 (7%) 2 (4%) 9 (6%)
Nebivolol 6 (21%) 16 (23%) 9 (17%) 31 (21%)
a1-Antagonists 3 (11%) 4 (6%) 2 (4%) 9 (6%)
Doxasosin 2 (7%) 3 (4%) 0 5 (3%)
Prasosin 1 (4%) 1 (1%) 2 (4%) 4 (3%)
ACE-Inhibitor 0 0 0 0
Angiotensin receptor blockers 17 (61%) 31 (44%) 22 (42%) 70 (46%)
Irbesartan 6 (21%) 13 (19%) 11 (21%) 30 (20%)
Losartan 7 (25%) 15 (21%) 5 (10%) 27 (18%)
Telmisartan 1 (4%) 2 (3%) 4 (8%) 7 (5%)
Valsartan 3 (11%) 1 (1%) 2 (4%) 6 (4%)
Renin-Inhibitor 0 0 0 0
Ca-channel blockers 11 (39%) 20 (28%) 13 (25%) 44 (29%)
Amlodipine 11 (39%) 19 (27%) 11 (21%) 41 (27%)
Dilthiazem 0 1 (1%) 1 (2%) 2 (1%)
Verapamil 0 0 1 (2%) 1 (0.5%)
Imidazoline-I agonisms 2 (7%) 1 (1%) 2 (4%) 5 (3%)
Rilmenidin 2 (7%) 1 (1%) 2 (4%) 5 (3%)
Statin therapy 13 (46%) 36 (51%) 23 (44%) 72 (48%)
doi:10.1371/journal.pone.0093719.t001
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